Tuberculosis still remains one of the most common, communicable, and leading deadliest
diseases known to mankind throughout the world. Drug-resistance in Mycobacterium …

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB
epidemic. Recent efforts have focused on the development of whole-cell screening assays …

A critical unmet clinical need to combat the global tuberculosis epidemic is the development
of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively …

The recent development and spread of extensively drug-resistant and totally drug-resistant
resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new …

Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-
growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL …

A set of 14 imidazo [1, 2-a] pyridine-3-carboxamides was synthesized and screened against
Mycobacterium tuberculosis H37Rv. The minimum inhibitory concentrations of 12 of these …

High-throughput screening of a library of small polar molecules against Mycobacterium
tuberculosis led to the identification of a phthalimide-containing ester hit compound (1) …

A series of pyrazolo [1, 5-a] pyridine-3-carboxamide derivatives were designed and
synthesized as new anti-Mycobacterium tuberculosis (Mtb) agents. The compounds exhibit …

The design, synthesis, structure, and in vitro anticancer and antimycobacterial activity of new
hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives are described. The …

Increasing interest in the potent anti-tuberculosis activity and the novel target (QcrB) of
imidazo [1, 2-a] pyridine-3-carboxamides encouraged extended structure–activity …